Les Inscriptions à la Bibliothèque sont ouvertes en
ligne via le site: https://biblio.enp.edu.dz
Les Réinscriptions se font à :
• La Bibliothèque Annexe pour les étudiants en
2ème Année CPST
• La Bibliothèque Centrale pour les étudiants en Spécialités
A partir de cette page vous pouvez :
Retourner au premier écran avec les recherches... |
Détail de l'auteur
Auteur Jayesh R. Bellare
Documents disponibles écrits par cet auteur
Affiner la rechercheModeling the cytotoxicity of cisplatin / Vishnu Sresht in Industrial & engineering chemistry research, Vol. 50 N° 23 (Décembre 2011)
[article]
in Industrial & engineering chemistry research > Vol. 50 N° 23 (Décembre 2011) . - pp. 12872–12880
Titre : Modeling the cytotoxicity of cisplatin Type de document : texte imprimé Auteurs : Vishnu Sresht, Auteur ; Jayesh R. Bellare, Auteur ; Santosh K. Gupta, Auteur Année de publication : 2012 Article en page(s) : pp. 12872–12880 Note générale : Chimie industrielle Langues : Anglais (eng) Mots-clés : Cytotoxicity Cisplatin Résumé : Cisplatin has been the mainstay of chemotherapeutic efforts against several types of cancers for over 30 years. However, there is still much that is unknown regarding its mechanism of action. The several serious side effects of cisplatin therapy and the lack of consensus regarding the ideal dosage regimen necessitate the development of a quantitative model for cisplatin action. A first-level mathematical model is presented for the cytotoxicity of cisplatin which predicts the survival of cancer cells when subjected to a given dose of this antitumor drug. This model comprises of (i) an uptake model that describes the movement of cisplatin molecules from the extracellular medium to the cell nucleus and the formation (and repair) of cisplatin−DNA adducts and (ii) a tolerance model that relates the quantity of cisplatin−DNA adducts formed inside the cell nuclei in a tumor to the fraction of tumor cells that are killed. The predictions of the model are in good agreement with in vitro experimental data obtained for carcinoma cell lines. To the best of our knowledge, this is the first model combining the uptake of cisplatin (consistent with the biochemical mechanism of action) with cell death (based on cisplatin−DNA adducts). It predicts a Pareto-type set of dosage regimen (dosage, Cext, vs exposure time, texp) of cisplatin to obtain a desired chemotherapeutic efficacy. Some reported patient-data is consistent with this prediction DEWEY : 660 ISSN : 0888-5885 En ligne : http://pubs.acs.org/doi/abs/10.1021/ie102360e [article] Modeling the cytotoxicity of cisplatin [texte imprimé] / Vishnu Sresht, Auteur ; Jayesh R. Bellare, Auteur ; Santosh K. Gupta, Auteur . - 2012 . - pp. 12872–12880.
Chimie industrielle
Langues : Anglais (eng)
in Industrial & engineering chemistry research > Vol. 50 N° 23 (Décembre 2011) . - pp. 12872–12880
Mots-clés : Cytotoxicity Cisplatin Résumé : Cisplatin has been the mainstay of chemotherapeutic efforts against several types of cancers for over 30 years. However, there is still much that is unknown regarding its mechanism of action. The several serious side effects of cisplatin therapy and the lack of consensus regarding the ideal dosage regimen necessitate the development of a quantitative model for cisplatin action. A first-level mathematical model is presented for the cytotoxicity of cisplatin which predicts the survival of cancer cells when subjected to a given dose of this antitumor drug. This model comprises of (i) an uptake model that describes the movement of cisplatin molecules from the extracellular medium to the cell nucleus and the formation (and repair) of cisplatin−DNA adducts and (ii) a tolerance model that relates the quantity of cisplatin−DNA adducts formed inside the cell nuclei in a tumor to the fraction of tumor cells that are killed. The predictions of the model are in good agreement with in vitro experimental data obtained for carcinoma cell lines. To the best of our knowledge, this is the first model combining the uptake of cisplatin (consistent with the biochemical mechanism of action) with cell death (based on cisplatin−DNA adducts). It predicts a Pareto-type set of dosage regimen (dosage, Cext, vs exposure time, texp) of cisplatin to obtain a desired chemotherapeutic efficacy. Some reported patient-data is consistent with this prediction DEWEY : 660 ISSN : 0888-5885 En ligne : http://pubs.acs.org/doi/abs/10.1021/ie102360e